PMC:7170415 / 22836-24590 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"350","span":{"begin":933,"end":940},"obj":"Species"},{"id":"351","span":{"begin":1567,"end":1575},"obj":"Species"},{"id":"352","span":{"begin":1727,"end":1734},"obj":"Species"},{"id":"353","span":{"begin":945,"end":953},"obj":"Disease"},{"id":"354","span":{"begin":1055,"end":1064},"obj":"Disease"},{"id":"355","span":{"begin":1718,"end":1726},"obj":"Disease"}],"attributes":[{"id":"A350","pred":"tao:has_database_id","subj":"350","obj":"Tax:9606"},{"id":"A351","pred":"tao:has_database_id","subj":"351","obj":"Tax:9606"},{"id":"A352","pred":"tao:has_database_id","subj":"352","obj":"Tax:9606"},{"id":"A353","pred":"tao:has_database_id","subj":"353","obj":"MESH:C000657245"},{"id":"A354","pred":"tao:has_database_id","subj":"354","obj":"MESH:D007239"},{"id":"A355","pred":"tao:has_database_id","subj":"355","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T42","span":{"begin":47,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma24728"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T22","span":{"begin":47,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A22","pred":"uberon_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T102","span":{"begin":945,"end":953},"obj":"Disease"},{"id":"T103","span":{"begin":1055,"end":1064},"obj":"Disease"}],"attributes":[{"id":"A102","pred":"mondo_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A103","pred":"mondo_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T208","span":{"begin":32,"end":39},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T209","span":{"begin":47,"end":51},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T210","span":{"begin":55,"end":56},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T211","span":{"begin":114,"end":121},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T212","span":{"begin":388,"end":393},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T213","span":{"begin":675,"end":686},"obj":"http://purl.obolibrary.org/obo/OBI_0000968"},{"id":"T214","span":{"begin":698,"end":701},"obj":"http://purl.obolibrary.org/obo/CL_0000990"},{"id":"T215","span":{"begin":733,"end":735},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T216","span":{"begin":795,"end":799},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T217","span":{"begin":877,"end":881},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T218","span":{"begin":1109,"end":1116},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T219","span":{"begin":1182,"end":1193},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T220","span":{"begin":1348,"end":1355},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T221","span":{"begin":1361,"end":1364},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T222","span":{"begin":1528,"end":1535},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T223","span":{"begin":1614,"end":1621},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T34","span":{"begin":11,"end":17},"obj":"Chemical"},{"id":"T35","span":{"begin":418,"end":426},"obj":"Chemical"},{"id":"T36","span":{"begin":625,"end":637},"obj":"Chemical"},{"id":"T37","span":{"begin":633,"end":637},"obj":"Chemical"}],"attributes":[{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_34922"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_33893"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}

{"project":"LitCovid-sentences","denotations":[{"id":"T160","span":{"begin":0,"end":39},"obj":"Sentence"},{"id":"T161","span":{"begin":40,"end":204},"obj":"Sentence"},{"id":"T162","span":{"begin":205,"end":432},"obj":"Sentence"},{"id":"T163","span":{"begin":433,"end":602},"obj":"Sentence"},{"id":"T164","span":{"begin":603,"end":737},"obj":"Sentence"},{"id":"T165","span":{"begin":738,"end":896},"obj":"Sentence"},{"id":"T166","span":{"begin":897,"end":1065},"obj":"Sentence"},{"id":"T167","span":{"begin":1066,"end":1296},"obj":"Sentence"},{"id":"T168","span":{"begin":1297,"end":1384},"obj":"Sentence"},{"id":"T169","span":{"begin":1385,"end":1576},"obj":"Sentence"},{"id":"T170","span":{"begin":1577,"end":1754},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Scaling Up Access to Diagnostic Testing\nIn the face of a public health emergency, important first steps to expand testing capacity include relaxing and streamlining regulatory requirements and procedures. Local public health laboratories and academic diagnostic laboratories in the United States are being rapidly enabled to perform EUA-granted commercial assays and laboratory-developed tests using research use–only reagents (61). University research laboratories could also add capacity, although concerns exist regarding quality control and the absence of protocols for managing clinical specimens. Flexibility regarding nucleic acid extraction methods and amplification instruments when using CDC protocols is being introduced (34). National agencies are expeditiously making materials for test development and validation available to clinical laboratories and diagnostic test manufacturers.\nSafely evaluating clinically stable persons for COVID-19 at traditional health care access points is resource intensive and slow, and risks exposing staff to infection. Many jurisdictions are enabling innovative testing venues, such as external tents or drive-through or “phone booth” testing, as well as home assessment teams to expedite specimen collection while limiting potential exposures (62). Telemedicine combined with at-home nasal swab self-testing also has been proposed (63). Of importance, in jurisdictions without universal health care coverage, policy solutions must be introduced to eliminate financial barriers to testing for uninsured and underinsured patients. Efforts to increase accessibility of testing for multiple use cases need to be coupled to appropriate public health interventions to isolate infected persons and their contacts."}